The US National Cancer Institute starts a Phase II clinical trial with Innate Pharma's IPH2101

Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) announces that the National Cancer Institute (“NCI”, National Institutes of Health, “NIH”, Bethesda, Maryland, USA) has enrolled a first patient in a new Phase II clinical trial testing Innate Pharma’s anti-KIR monoclonal antibody IPH2101, in patients with smoldering myeloma, an early stage of the blood malignancy multiple myeloma.